Open-label, Fixed Sequence Crossover Study to Investigate the Effects of Carbamazepine on the Pharmacokinetics of Elinzanetant (BAY 3427080) in Healthy Participants.
Latest Information Update: 28 Feb 2022
Price :
$35 *
At a glance
- Drugs Elinzanetant (Primary) ; Carbamazepine; Midazolam
- Indications Sex hormone disorders; Vasomotor symptoms
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 10 Dec 2021 Planned End Date changed from 17 Jan 2022 to 27 Jan 2022.
- 10 Nov 2021 Status changed from recruiting to active, no longer recruiting.